PharmaShots Weekly Snapshots (March 21 - 25, 2022)
Published: Mar 25, 2022 | Tags: LEO Pharma, P-III, ECZTEND Trial, Adbry, tralokinumab-ldrm, Atopic Dermatitis, AAD 2022
Published: Mar 25, 2022 | Tags: Janssen, Cabenuva, rilpivirine, cabotegravir, US, FDA, Label Update, Approval, HIV
Medtronic Reports the First Patient Implant in (TITAN 2) Study of Implantable Tibial Neuromodulation Device for Overactive Bladder
Published: Mar 25, 2022 | Tags: Medtronic, TITAN 2 Study, Implantable Tibial Neuromodulation Device, Overactive Bladder
Published: Mar 25, 2022 | Tags: Jazz, P-II, EMERGE-201, Basket Trial, Zepzelca, lurbinectedin, Solid Tumors
Published: Mar 25, 2022 | Tags: AstraZeneca, Evusheld, Approval, EU, Pre-Exposure Prophylaxis, COVID-19
Published: Mar 25, 2022 | Tags: Halozyme, Chugai, Enhanze, Drug-Delivery Technology
Published: Mar 24, 2022 | Tags: Pfizer, Respiratory Syncytial Virus Vaccine, PF-06928316, RSVpreF, US, FDA, Breakthrough Therapy Designation, RSV
PharmaTher Reports Results of Ketamine in a Clinical Study for the Treatment of Parkinson’s Disease
Published: Mar 24, 2022 | Tags: PharmaTher, Ketamine, Parkinson’s Disease
Published: Mar 24, 2022 | Tags: argenx, Vyvgart, efgartigimod alfa-fcab, P-III, ADAPT-SC Study, Generalized Myasthenia Gravis
Published: Mar 24, 2022 | Tags: Silence, Mallinckrodt, Clinical Trial Application, SLN501, Complement-Mediated Diseases
Published: Mar 24, 2022 | Tags: Moderna, COVID-19 Vaccine, mRNA-1273, P-II/III, KidCOVE Study
Published: Mar 24, 2022 | Tags: Pfizer, Etrasimod, P-III, ELEVATE 12 Trial, Ulcerative Colitis
GSK Entered into a R&D Collaboration with LifeMine to Discover Novel Therapies for Multiple Disease
Published: Mar 23, 2022 | Tags: GSK, LifeMine, Avatar-Rx Platform, Multiple Disease
Published: Mar 23, 2022 | Tags: Palisade Bio, US, FDA, P-III, Clinical Trial, LB1148, Bowel Function, Abdominal Surgery
Published: Mar 23, 2022 | Tags: Novavax, Serum Institute of India, NVX-CoV2373, DCGI, EUA, COVID-19, India
Published: Mar 23, 2022 | Tags: Aligos, ALG-020572, ALG-020572-401 Study, Chronic Hepatitis B
Published: Mar 23, 2022 | Tags: BioMarin, Vimizin, elosulfase alfa, NICE, Recommendation, Mucopolysaccharidosis Type 4A
Published: Mar 23, 2022 | Tags: ObsEva, Linzagolix, P-III, EDELWEISS 3 Trial, Endometriosis-Associated Pain
Published: Mar 22, 2022 | Tags: Plus Therapeutics P-I/IIa, ReSPECT-LM, Dose Escalation Trial, 186RNL, Leptomeningeal Metastases
Published: Mar 22, 2022 | Tags: GeNeuro, Temelimab, Rituximab, P-II, ProTEct-MS Trial, Multiple Sclerosis
Published: Mar 22, 2022 | Tags: Ascentage Pharma, Alrizomadlin, APG-115, US, FDA, Rare Pediatric Disease Designation, Neuroblastoma
Published: Mar 22, 2022 | Tags: uniQure, P-I/II Trial, AMT-130, Huntington’s Disease
Tonix Reports Results of TNX-102 SL in P-III (RALLY) Study for the Treatment of Fibromyalgia
Published: Mar 22, 2022 | Tags: Tonix, TNX-102 SL, P-III, RALLY Study, Fibromyalgia
Published: Mar 22, 2022 | Tags: Merck, Keytruda, pembrolizumab, US, FDA, Approval, MSI‑H/dMMR, Endometrial Carcinoma
Nuance Pharma Signs a License and Supply Agreement with Bavarian Nordic to Develop and Commercialize of Respiratory Syncytial Virus Vaccine
Published: Mar 21, 2022 | Tags: Nuance Pharma, Bavarian Nordic, Respiratory Syncytial Virus Vaccine,
Published: Mar 21, 2022 | Tags: Scilex, Semdexa, SP-102, P-III, C.L.E.A.R. Program, Sciatica Pain Management
BMS Collaborated with Volastra to Develop and Commercialize Novel Therapies for Cancer
Published: Mar 21, 2022 | Tags: BMS, Volastra, Therapies, Cancer, CINtech platform
Published: Mar 21, 2022 | Tags: Marinus, Ztalmy, ganaxolone, US, FDA, Approval, CDKL5 Deficiency Disorder
Published: Mar 21, 2022 | Tags: Merck, Keytruda, pembrolizumab, P-III, KEYNOTE-09 Trial, Stage IB-IIIA, NSCLC, PD-L1 Expression
Published: Mar 21, 2022 | Tags: BMS, Opdualag, nivolumab, relatlimab-rmbw, US, FDA, Approval, Metastatic, Melanoma
Related Post: PharmaShots Weekly Snapshots (March 07-11, 2022)
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com